Profile data is unavailable for this security.
About the company
Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
- Revenue in USD (TTM)139.91m
- Net income in USD-140.75m
- Incorporated1996
- Employees371.00
- LocationAvid Bioservices Inc14191 MYFORD ROADTUSTIN 92780United StatesUSA
- Phone+1 (714) 508-6100
- Fax+1 (714) 838-5817
- Websitehttps://avidbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 5.44m | -96.91m | 405.13m | 202.00 | -- | 4.14 | -- | 74.49 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 414.75m | 357.00 | -- | 1.99 | -- | 2.45 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 418.84m | 597.00 | -- | -- | -- | 1.77 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | 396,390.30 | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 456.60m | 240.00 | -- | -- | -- | 1.99 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 465.11m | 121.00 | -- | 1.78 | -- | 9.30 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 498.00m | 99.00 | -- | 2.43 | -- | 8.10 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| SNDL Inc | 657.63m | -99.25m | 599.93m | 2.52k | -- | 0.6726 | -- | 0.9123 | -0.3791 | -0.3879 | 2.52 | 3.37 | 0.5855 | 4.67 | 33.35 | 261,378.30 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 600.53m | 1.60k | -- | 0.9045 | -- | 0.5066 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Avid Bioservices Inc | 139.91m | -140.75m | 609.74m | 371.00 | -- | 10.01 | -- | 4.36 | -2.22 | -2.22 | 2.21 | 0.9579 | 0.355 | 3.57 | 4.92 | 377,118.60 | -35.72 | -0.826 | -56.03 | -1.20 | 5.23 | 19.26 | -100.60 | -2.14 | 1.04 | -4.30 | 0.727 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| PetIQ Inc | 1.12bn | 7.34m | 634.01m | 1.93k | 98.83 | 2.68 | 11.69 | 0.5661 | 0.2156 | 0.2156 | 36.40 | 7.95 | 1.29 | 4.58 | 5.67 | 579,376.60 | 0.8933 | -4.32 | 1.14 | -5.23 | 23.66 | 20.05 | 0.6951 | -3.66 | 1.25 | 1.84 | 0.6517 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -126.64m | 647.02m | 150.00 | -- | 3.12 | -- | -- | -3.40 | -3.40 | 0.00 | 4.86 | 0.00 | -- | -- | 0.00 | -60.51 | -40.63 | -66.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| SIGA Technologies Inc | 157.02m | 79.26m | 683.49m | 45.00 | 8.77 | 4.14 | 8.56 | 4.35 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 755.88m | 158.00 | -- | 1.73 | -- | 3,047.91 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 767.54m | 1.92k | 58.33 | 2.84 | 15.76 | 0.7679 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Evolus Inc | 219.70m | -60.00m | 770.74m | 279.00 | -- | 41.57 | -- | 3.51 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Data as of Jul 23 2024. Currency figures normalised to Avid Bioservices Inc's reporting currency: US Dollar USD
54.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.85m | 9.21% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.46m | 7.03% |
| Millennium Management LLCas of 31 Mar 2024 | 4.40m | 6.94% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.49m | 5.50% |
| Point72 Asset Management LPas of 25 Apr 2024 | 3.23m | 5.08% |
| AltraVue Capital LLCas of 31 Mar 2024 | 3.16m | 4.97% |
| 12 West Capital Management LPas of 31 Mar 2024 | 2.75m | 4.33% |
| RBC Global Asset Management (US), Inc.as of 31 Mar 2024 | 2.59m | 4.08% |
| Snyder Capital Management LPas of 31 Mar 2024 | 2.18m | 3.44% |
| Palisade Capital Management LPas of 31 Mar 2024 | 2.17m | 3.42% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
